AstraZeneca Pharma India share news, announcements and annual reports
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
AstraZeneca Pharma India Limited · Formerly Astra IDL · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1982 on BSE, May 2001 on NSE
Last close ₹6,364.50up ₹65.50 (1.04%)BSE ₹6,367.35
Share price at the NSE close on 30 Oct 2026. Previous close ₹6,299.00.
30 Oct: open ₹6,300.00, high ₹6,380.00, low ₹6,240.50
52-week range of traded prices to 30 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,911 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 93.81
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.23
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,84556.8% delivered
AstraZeneca Pharma India record dates, bonuses and splits
10 filed, newest first.
Jul 2026
18 Jul · Corporate action
Jul 2025
11 Jul · Corporate action
Jun 2024
25 Jun · Corporate action
Jul 2023
3 Jul · Corporate action
Jun 2022
27 Jun · Corporate action
Aug 2021
9 Aug · Corporate action
Aug 2020
11 Aug · Corporate action
Aug 2019
7 Aug · Corporate action
Dec 2008
1 Dec · Corporate action
The 8% secured fully paid-up redeemable non-convertible Debentures of face value of Rs. 25/- each (Bonus Debentures), issued by the Company on January 12, 2008, pursuant to the Scheme of Arrangement approved by the Hon'ble High Court of Karnataka are falling due for redemption on January 11, 2009 (Redemption Date).The Company has fixed December 26, 2008 as the Record Date for determining the entitlement of the eligible Debentureholders to receive the principal amount together with the interest accrued on the said Bonus Debentures upto the Redemption Date
Dec 2007
20 Dec · Corporate action
Consequent to the Order of the High Court of Karnataka sanctioning the Scheme under Section 391 of the Companies Act, 1956, the Company has now received the no-objection from the Reserve Bank of India (RBI) to the same. Accordingly, in terms of the Scheme, the Company would be initiating further steps for issuance of Bonus Debentures aggregating to Rs.62.50 crores, in the ratio of one debenture of the face value of Rs.25/- each for every equity share held by the shareholders as on the Record Date, redeemable at the end of 12 months from the date of allotment. The Company has fixed Friday, January 11, 2008, as the Record Date for determining the entitlement of shareholders to receive the Bonus Debentures